Address the challenges and accelerate the design and development of efficacious vaccines


Lonza’s proprietary Epibase® in vitro Immunogenicity Screening Service includes a wide range of assays to assess the immune response induced by vaccine candidates.  The immunogenicity potential of a vaccine is evaluated by directly measuring the immune response induced in human peripheral blood mononuclear cells (PBMCs). Epibase® in vitro allows for a direct comparison of the immune response induced by multiple vaccine leads.  When combined with our proprietary Epibase® in silico tool, these cellular assays allow for a comprehensive immunogenicity assessment of your vaccine leads.  The tools aid in the selection of optimal vaccine leads helping to maximize an effective immune response in humans prior to embarking on clinical trials.

The Epibase® in vitro assays use PBMCs providing researchers with an immune response that closely resembles the response in a human.  For the Epibase®  in vitro assays, whole blood is collected at Phase I clinical sites adhering to ethically approved protocols.

  • PBMCs isolated and cryopreserved within 8 hours of blood withdrawal
  • Donors genotyped to a 4-digit level at HLA Class I and II loci
  • Stringent quality control analysis, including cell viability, functionality and sub-population

Lonza routinely isolates PBMCs from healthy donors and has access to over 200,000 healthy donors at a number of Phase I clinical trial sites. Lonza also has the option to source specific disease patients or tailor the population by ethnicity, gender and age. This allows leads to be tested in a population representative of the disease and target patient population.

 

LPB-T.83-Epibase®invitroScreeningforBiotherapeutics-ScreeningDiagram

Designed for a Wide Range of Targets:

  • Whole proteins and protein complexes  
  • Peptides and peptide pools
  • Viral proteins
  • Virus-like particles (VLPs) and virosomes
  • Adjuvants  

Advantages of Epibase® in vitro assays:

  • Multi-parameter measurement of human primary immune cell activation by flow cytometry, FluoroSpot and Luminex® allows for a comprehensive characterization of the immune response
  • High throughput processes capable of running large panels of samples
  • Stringent quality control to promote assay consistency and traceability of each sample
  • Consistent supply of diverse, high quality PBMC samples from healthy human donors
  • PBMC can also be isolated from specific patient groups to characterize the immune response in the disease background (taking into account patient genetics, immune status and concomitant medication)